WLLW vs. ASP, RTI, ENTG, NU, AQS, VIV, ATT, AGRA, MJ, and BIO
Should you be buying Willow Biosciences stock or one of its competitors? The main competitors of Willow Biosciences include Acerus Pharmaceuticals (ASP), Radient Technologies (RTI), Entourage Health (ENTG), NeutriSci International (NU), Aequus Pharmaceuticals (AQS), Avivagen (VIV), Abattis Bioceuticals (ATT), Agraflora Organics International (AGRA), Amplify Alternative Harvest ETF (MJ), and Bio-Rad Laboratories (BIO). These companies are all part of the "drug manufacturers - specialty & generic" industry.
Willow Biosciences vs.
Acerus Pharmaceuticals (TSE:ASP) and Willow Biosciences (TSE:WLLW) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, community ranking, risk, analyst recommendations, institutional ownership, valuation and earnings.
Acerus Pharmaceuticals has a net margin of 0.00% compared to Willow Biosciences' net margin of -268.91%. Acerus Pharmaceuticals' return on equity of 0.00% beat Willow Biosciences' return on equity.
0.1% of Willow Biosciences shares are owned by institutional investors. 91.4% of Acerus Pharmaceuticals shares are owned by company insiders. Comparatively, 24.3% of Willow Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Acerus Pharmaceuticals received 109 more outperform votes than Willow Biosciences when rated by MarketBeat users. However, 82.35% of users gave Willow Biosciences an outperform vote while only 66.49% of users gave Acerus Pharmaceuticals an outperform vote.
Willow Biosciences has lower revenue, but higher earnings than Acerus Pharmaceuticals. Willow Biosciences is trading at a lower price-to-earnings ratio than Acerus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Willow Biosciences had 1 more articles in the media than Acerus Pharmaceuticals. MarketBeat recorded 1 mentions for Willow Biosciences and 0 mentions for Acerus Pharmaceuticals. Willow Biosciences' average media sentiment score of 0.80 beat Acerus Pharmaceuticals' score of 0.00 indicating that Willow Biosciences is being referred to more favorably in the news media.
Acerus Pharmaceuticals has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500. Comparatively, Willow Biosciences has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500.
Summary
Acerus Pharmaceuticals and Willow Biosciences tied by winning 7 of the 14 factors compared between the two stocks.
Get Willow Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for WLLW and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Willow Biosciences Competitors List
Related Companies and Tools
This page (TSE:WLLW) was last updated on 5/1/2025 by MarketBeat.com Staff
Buy WLLW Stock Free WLLW Stock Alerts